GMP manufacturing & GLP diagnostic: Towards a personalised phage therapy against antimicrobial resistance

Projektinformationen

PhagoPROD

ID Finanzhilfevereinbarung: 811749

DOI 10.3030/811749

Abgeschlossenes Projekt

EK-Unterschriftsdatum 25 Juli 2018

Startdatum 1 November 2018

Enddatum 31 Dezember 2021

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten € 3 929 376,00

EU-Beitrag € 2 446 712,00

Koordiniert durch

PHERECYDES PHARMA SA
France

Ziel

Phage therapy, that is the therapeutic use of bacteriophages for the treatment of pathogenic bacterial infections, is a highly promising answer to the antibiotic resistant plague (500 000 deaths a year attributable to multi-drug resistant bacteria today, 10 million forecast by 2050). In this hopeful field, Pherecydes Pharma, a French SME created in 2006, is currently the world leader of phage therapy, with a a unique selling point and value proposal: (1) Patented technology; (2) Curent product portfolio covering over 50% of human infections and almost 90% of multi-drug resistant ones; (3) Ability to manufacture phages in GMP conditions; (4) 1st company to launch a transnational, well-designed, well-controlled, multicentric clinical study; (5) French authorisation (ANSM) in 2017 to administrate Pherecydes Pharma bacteriophages under a compassionate use status. Building on these successes, the PhagoPROD project aims at setting-up, optimising and scaling-up the GMP manufacturing and GLP diagnostics processes currently validated and demonstrated at laboratory scale. In that so, the ultimate objective is to achieve large-scale commercial exploitation of Pherecydes Pharma products first at the EU then at the USA levels (world reaching is planned in the long term). In the frame of this future commercial exploitation, targeted final users will be patients suffering from bacterial infections, notably antibiotic-resistant ones. Customers (i.e. buyers of Pherecydes Pharma products) will be clinical prescribers and hospital pharmacists. In this regard, Pherecydes already benefits from strong and long-lasting relationships with many hospitals and clinical centres in France and in Europe, as well as with several patients' associations (e.g. Le Lien or Phagespoirs).

Wissenschaftliches Gebiet

• natural sciences › biological sciences › microbiology › bacteriology
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• natural sciences › biological sciences › microbiology › virology
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance › multidrug resistance
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance › antibiotic resistance

Programm/Programme

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Thema/Themen

• EIC-SMEInst-2018-2020 - SME instrument

Aufforderung zur Vorschlagseinreichung

H2020-EIC-SMEInst-2018-2020

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEInst-2018-2020-2

Finanzierungsplan

SME-2 - SME instrument phase 2

Koordinator

PHERECYDES PHARMA SA

• Netto-EU-Beitrag: € 2 446 712,00
• Adresse: NANTES BIOTECH 22 BOULEVARD BENONI GOULLIN ; 44200 NANTES ; Frankreich
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Pays de la Loire › Pays de la Loire › Loire-Atlantique
• Region: Pays de la Loire › Pays de la Loire › Loire-Atlantique
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 3 929 376,00